Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis

Archives of Neurology

Volumn 62, Issue 4, 2005, Pages 569-573

  Sastre Garriga, J ^a   Ingle, G T ^a   Chard, D T ^a   Ramio Torrenta Li ^a   McLean, M A ^a   Miller, D H ^a   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

ADULT; AGE OF ONSET; AGED; ASPARTIC ACID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; CHOLINE; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; GLUTAMIC ACID; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NERVE FIBERS, MYELINATED; NEURONS; NEUROPIL; PHOSPHOCREATINE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; STATISTICS;

EID: 16844384074     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.4.569     Document Type: Article

References (25)

1. Davie CA, Barker GJ, Webb S, et al. Persistent deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 1995;118:1583-1592.
2. Wolinsky JS, Narayana PA. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr Opin Neurol. 2002;15:247-251.
3. 1H-MRSI of cerebral gray and white matter. Magn Reson Med. 2000;44:401-411.
4. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120:1085-1096.
5. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999;122:17-26.
6. Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging, 2002;15:259-267.
7. Chard DT, McLean MA, Parker GJ, MacManus DG, Miller DH. Reproducibility of in vivo metabolite quantification with proton magnetic resonance spectroscopic imaging. J Magn Reson Imaging. 2002;15:219-225.
8. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, 5: the clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122:625-639.
9. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal-appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63:736-742.
10. 1H magnetic resonance spectroscopy of normal-appearing white matter in primary progressive multiple sclerosis. J Neurol. 1999;246:1023-1026.
11. 1H magnetic resonance spectroscopy of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000;6:148-155.
12. Cucurella MG, Rovira A, Rio J, et al. Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed. 2000;13:57-63.
13. Pan JW, Coyle PK, Bashir K, Whitaker JN, Krupp LB, Hetherington HP. Metabolic differences between multiple sclerosis subtypes measured by quantitative MR spectroscopy. Mult Scler. 2002;8:200-206.
14. Sarchielli P, Presciutti O, Pelliciolli P, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain. 1999;122:513-521.
15. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Brain. 1998;121:1469-1477.
16. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;60:1157-1162.
17. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47:831-835.
18. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679.
19. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical gray and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:2342-2352.
20. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127:1361-1369.
21. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15:289-298.
22. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci. 1979;41:81-91.
23. 13C NMR. Proc Natl Acad Sci U S A. 1999;96:8235-8240.
24. Petroff OA, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Magn Reson Imaging. 1995;13:1197-1211.
25. 1H NMR spectroscopy. NMR Biomed. 2002;15:375-384.